0000899243-17-026034.txt : 20171113 0000899243-17-026034.hdr.sgml : 20171110 20171113162722 ACCESSION NUMBER: 0000899243-17-026034 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20171113 FILED AS OF DATE: 20171113 DATE AS OF CHANGE: 20171113 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: venBio Global Strategic Fund II L.P. CENTRAL INDEX KEY: 0001634632 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38276 FILM NUMBER: 171196255 BUSINESS ADDRESS: STREET 1: 1700 OWENS STREET STREET 2: SUITE 595 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: 415-522-0100 MAIL ADDRESS: STREET 1: 1700 OWENS STREET STREET 2: SUITE 595 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Apellis Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001492422 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 271537290 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6400 WESTWIND WAY STREET 2: SUITE A CITY: CRESTWOOD STATE: KY ZIP: 40014 BUSINESS PHONE: 502-241-4114 MAIL ADDRESS: STREET 1: 6400 WESTWIND WAY STREET 2: SUITE A CITY: CRESTWOOD STATE: KY ZIP: 40014 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-11-13 1 0001492422 Apellis Pharmaceuticals, Inc. APLS 0001634632 venBio Global Strategic Fund II L.P. 1700 OWENS STREET, SUITE 595 SAN FRANCISCO CA 94158 0 0 1 0 Common Stock 2017-11-13 4 C 0 3451790 A 3451790 D Common Stock 2017-11-13 4 P 0 127515 14.00 A 3579305 D Series D Preferred Stock 2017-11-13 4 C 0 6714413 0.00 D Common Stock 3147872 0 D Series E Preferred Stock 2017-11-13 4 C 0 648256 0.00 D Common Stock 303917 0 D The Series D and Series E Preferred Stock converted into Common Stock on a 2.133-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D and Series E Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. Robert Adelman and Corey Goodman, the managing partners of venBio Global Strategic Fund II LP ("venBio"), share voting and dispositive control over the shares held by venBio. /s/ Robert Adelman 2017-11-13